ipharmacenter Consulting services

Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity. A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau 54% of participants on the 24 mg dose achieved resolution of obesity (BMI <30 kg/m2) vs. 13% in the placebo group. CT-388 demonstrated a safety and tol

Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to manufacture and commercialize a generic variant of semaglutide injection in the domestic market. The therapy, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, is intended for long-term weight management in adults when combined with a healthy diet and regular physical activity.   The company will introduce its generic semaglutide injection under the b

Aspect Biosystems and Novo Nordisk have agreed to expand and reshape their existing collaboration to accelerate the development of cell‑based therapies intended to transform the treatment of diabetes. The updated agreement marks a move into a new phase of the partnership, with Aspect assuming broader control of core programmes and Novo Nordisk contributing additional technologies, capabilities and funding. Also read: Top selling drugs | 2026 The companies have been working to

Lilly's Tirzepatide Outperforms Semaglutide in Weight Loss Trial Also read: Top selling cancer drugs of 2024 Eli Lilly and Company...

Treatment with tirzepatide in adults with prediabetes and either obesity or overweight conditions has led to substantial weight loss and...

Pfizer Progresses with Once-Daily Oral GLP-1 Receptor Agonist Danuglipron Pfizer has reported positive pharmacokinetic results from...

Boehringer Ingelheim has revealed its strategic plan to propel survodutide, a dual agonist for the glucagon/GLP-1 receptor, into three...

Sanofi has reduced the price of Lantus (insulin glargine injection) 100 Units/mL by 78%, which is Sanofi's most widely prescribed...

May 26, 2022 FDA granted fast track designation for ervogastat/clesacostat for the treatment of NASH Pizer announced that the U.S. Food...